Top Suppliers:I want be here
Related CAS#:
955553-59-0 908544-50-3
908544-78-5 908544-80-9
955581-62-1 955569-03-6
955569-06-9 908551-93-9
908551-96-2 955581-70-1

100986-85-4

100986-85-4 structure
100986-85-4 structure
  • Name: Levofloxacin
  • Chemical Name: levofloxacin
  • CAS Number: 100986-85-4
  • Molecular Formula: C18H20FN3O4
  • Molecular Weight: 361.367
  • Catalog: API Synthetic anti-infective drugs Quinolone
  • Create Date: 2018-02-05 08:00:00
  • Modify Date: 2026-07-20 11:31:36
  • Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3].
Name levofloxacin
Synonyms Levofloxcin
S-(-)-9-Fluom-2，3-dihydrcr3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1，2，3-de]-1，4-benzoxazine-6-cboxylic acid hemihydrate
Levofloxacin heMihydrate API
Quixin
S-(-)-Ofloxacin
Levofloxacin HeMihidrated
Erlotinib-d13 HCl
Ophthalmic
dr3355
RiMantadin
Veteriny Medicine Ofloxacin Powder CAS100-4)
(s)-ofloxacin
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-cboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)
(3S)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Levofloxacin>
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-cboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)- (9CI)
Levofloxacine hemidrate
Levofloxacin, HeMihydrate
(-)-Ofloxacin
LEVOFLOXACIN HCL
Levofloxacin solution
(3S)-9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Levofloxacin hydrochloride //BP
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-1 0-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5,6,8,11-tetraene-11-cboxylic acid
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazin-yl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-cboxylic acid
acid Monohydrochloride
[3S,(-)]-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-cboxylic acid
Levofloxacin(Levaquin)
Lecofloxacin
Tavanic
Levofloxacin hemyhydrate
LEVOFLOXACIN
(S)-Ofloxacin,e.e
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-cboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)
LevofloxacinQ: What is Levofloxacin Q: What is the CAS Number of Levofloxacin Q: What is the storage condition of Levofloxacin Q: What e the applications of Levofloxacin
evofL
(S)-9, 10-DIFLUORO-3-METHYL-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CBOXYLIC ACID
RWJ 25
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-cboxylic Acid Hemihydrate
(3s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-cboxylic acid monohydrochloride
(S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-cboxylic acid
MFCD03265511
Crit
Levaquin
Levofloxacin Levofloxacin
Cravit
levoflaxacin
Levofloxacin base
Levofloxacin (LVX)
L-Ofloxacin
hemihydrate,(s)-ethyl-10-(4-methyl-1-piperazinyl)-7-oxo
Lelofloxacin
Mesylate Levofloxacin
Phmaceutical Intermediates Levofloxacin base
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-cboxylicacid,2,3-dihydro-9-fluoro-3-m
(S)-9-fluoro-3-Methyl-10-(4-Methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-cboxylic acid
Description Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3].
Related Catalog
References

[1]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.

[2]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.

[3]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.
Density 1.5±0.1 g/cm3
Boiling Point 571.5±50.0 °C at 760 mmHg
Melting Point 218ºC
Molecular Formula C18H20FN3O4
Molecular Weight 361.367
Flash Point 299.4±30.1 °C
Exact Mass 361.143799
PSA 75.01000
LogP 0.84
Vapour Pressure 0.0±1.7 mmHg at 25°C
Index of Refraction 1.670
Storage condition Store at 0-5°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UU8815550
CHEMICAL NAME :
7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl- 10-(4-methyl-1-piperazinyl)-7-oxo-, hemihydrate, (S)-
CAS REGISTRY NUMBER :
100986-85-4
LAST UPDATED :
199403
DATA ITEMS CITED :
8
MOLECULAR FORMULA :
C18-H20-F-N3-O4.1/2H2-O
MOLECULAR WEIGHT :
342.41

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1478 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,365,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1803 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,365,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
>250 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,365,1992 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
14560 mg/kg/26W-I
TOXIC EFFECTS :
Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in leukocyte (WBC) count
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,367,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
22400 mg/kg/28D-I
TOXIC EFFECTS :
Gastrointestinal - other changes Blood - changes in leukocyte (WBC) count Nutritional and Gross Metabolic - changes in phosphorus
REFERENCE :
JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 16,29,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
2800 mg/kg/28D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - urine volume decreased Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 16,29,1991 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8910 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,374,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
8910 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,374,1992
Symbol GHS07 GHS08
GHS07, GHS08
Signal Word Danger
Hazard Statements H302-H317-H334-H361d-H362
Precautionary Statements P261-P263-P280-P342 + P311
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Faceshields;Gloves
Hazard Codes Xn: Harmful;
Risk Phrases R22
Safety Phrases 26-36/37/39-36
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS UU8815550
HS Code 2934999090
HS Code 2934999090
Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:100986-85-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 100986-85-4 | Chemsrc address: https://m.chemsrc.com/en/baike/345636.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved